Application 206858
- Type
- ANDA
- Sponsor
- MYLAN PHARMS INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | DALFAMPRIDINE | DALFAMPRIDINE | TABLET, EXTENDED RELEASE;ORAL | 10MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A206858-001 | DALFAMPRIDINE | DALFAMPRIDINE | 10MG | TABLET, EXTENDED RELEASE / ORAL | 2020-07-06 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A206858-001 | DALFAMPRIDINE | 10MG | TABLET, EXTENDED RELEASE / ORAL | 2020-07-06 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Dalfampridine | DALFAMPRIDINE | Accord Healthcare Inc. | 354a97e8-35c8-418b-91b2-9e8e066cec65 | 2026-11-06 | Warnings, Adverse reactions | Dalfampridine DALFAMPRIDINE |
| Dalfampridine | DALFAMPRIDINE | Golden State Medical Supply, Inc. | 1134ac0f-59c1-a20b-e063-6294a90affcc | 2026-07-28 | Warnings, Adverse reactions | Dalfampridine DALFAMPRIDINE |
| Dalfampridine | DALFAMPRIDINE | Ascend Laboratories, LLC | e10b2d92-2824-4395-8883-6fd52c784aa4 | 2026-07-14 | Warnings, Adverse reactions | Dalfampridine DALFAMPRIDINE |
| AMPYRA | DALFAMPRIDINE | Merz Pharmaceuticals, LLC | 550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783 | 2026-01-16 | Warnings, Adverse reactions | DALFAMPRIDINE |
| DALFAMPRIDINE | DALFAMPRIDINE | Micro Labs Limited | 302c8270-4711-4ca4-bee8-be0738fbe094 | 2025-07-28 | Warnings, Adverse reactions | DALFAMPRIDINE DALFAMPRIDINE |
| Dalfampridine | DALFAMPRIDINE | CivicaScript LLC | c40dcc84-b839-44aa-94f2-886fb1c3d75c | 2025-07-16 | Warnings, Adverse reactions | Dalfampridine DALFAMPRIDINE |
| AMPYRA | DALFAMPRIDINE | Merz Pharmaceuticals, LLC | 974fb2af-7012-4989-b330-e44a31c9c3e5 | 2025-05-05 | Warnings, Adverse reactions | DALFAMPRIDINE |
| DALFAMPRIDINE | DALFAMPRIDINE | Bryant Ranch Prepack | 688eb479-debc-4cfc-a74d-14828c347049 | 2025-02-12 | Warnings, Adverse reactions | DALFAMPRIDINE DALFAMPRIDINE |
| DALFAMPRIDINE | DALFAMPRIDINE | Aurobindo Pharma Limited | 43996322-7d83-4420-9e61-4ed37f710fee | 2024-02-15 | Warnings, Adverse reactions | DALFAMPRIDINE DALFAMPRIDINE |
| Dalfampridine | DALFAMPRIDINE | Sun Pharmaceutical Industries, Inc. | d61e15fa-0334-49a0-ab41-c9a36b726b57 | 2023-10-16 | Warnings, Adverse reactions | Dalfampridine DALFAMPRIDINE |
| Dalfampridine | DALFAMPRIDINE | Actavis Pharma, Inc. | ed826777-b8c4-4d35-aa64-a4c28452baa8 | 2021-12-01 | Warnings, Adverse reactions | Dalfampridine DALFAMPRIDINE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0378-4504 | dalfampridine | dalfampridine | Mylan Pharmaceuticals Inc. | ANDA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 45738 | ORIG | 2016-11-01 |